

IMMUNOCORE

Immunocore to present at upcoming investor conferences

October 30, 2023

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor conferences in November:

- **TD Cowen Fall Oncology Innovation Summit: Insights for SITC and ASH**
Fireside Chat: Friday, November 3, 2023, at 2:20 p.m. EDT
- **Truist Securities BioPharma Symposium**
1x1 and small group meetings: Wednesday, November 8, 2023
- **Jefferies London Healthcare Conference**
Fireside Chat: Tuesday, November 14, 2023, at 2:30 p.m. GMT
- **3rd Annual BTIG Ophthalmology Day**
Fireside Chat: Monday, November 27, 2023, at 10:30 a.m. EST

Where relevant, the presentations will be webcast live and can be accessed by visiting 'Events', under 'News & Events', via the 'Investors' section of Immunocore's website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including four clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company's most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT:

Immunocore

Sébastien Desprez, Head of Communications

T: +44 (0) 7458030732

E: sebastien.desprez@immunocore.com

Follow on Twitter: @Immunocore

Investor Relations

Clayton Robertson, Head of Investor Relations

T: +1 215-384-4781

E: ir@immunocore.com